SEEING BLUES ALL AROUND

A CASE OF PROPYLTHIOURACIL-INDUCED CYANOPSIA

Authors

  • Noor Hafis Md Tob
  • Chin Voon Tong
  • Joel Xiang Loong Lee
  • Siow Ping Lee
  • Melissa Vergis

Keywords:

PROPYLTHIOURACIL-INDUCED CYANOPSIA, CYANOPSIA, PTU

Abstract

INTRODUCTION/BACKGROUND
Cyanopsia is a subjective symptom characterized by a bluish appearance of the overall visual field and has been reported among patients taking phosphodiesterase-5 inhibitors. Propylthiouracil (PTU) is a member of the thiouracil group and widely used for the treatment of thyrotoxicosis. Despite being associated with various side effects, such as hepatitis, agranulocytosis, body rash, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, PTU-related cyanopsia has not been reported.

CASE
In this report, we describe a case of PTU-induced cyanopsia, including the results of biochemical laboratory tests. We also discuss treatment strategies and include literature review. A 33-year-old female presented with palpitations and tremors. Clinically, she appeared anxious with hand tremor and diffuse goiter. Her pulse was regular, and other systemic examinations were unremarkable. Thyroid function tests (TFTs) showed overt hyperthyroidism with suppressed thyroid-stimulating hormone (TSH) levels (<0.008 miu/L) and high free T4 levels (55.9 pmol/L). She was treated for Grave’s disease with carbimazole but developed significant urticaria. PTU was then introduced, but she developed a bluish appearance of her surrounding vision right after the second dose. The symptoms subsided after one day of discontinuing PTU. Re-challenging with PTU at a lower dose also resulted in a similar effect. Eye assessment by ophthalmology was normal. She was then given propranolol and cholestyramine to control her thyroid status. Definitive treatment with radioactive iodine will be administered once her thyroid function improves. PTU is one of the mainstay oral medications for hyperthyroidism and is generally well-tolerated. However, PTU-induced cyanopsia may limit oral treatment options, although the phenomenon appears reversible after stopping medication, regardless of the dose. It may cause significant distress and lead to discontinuation of treatment.

CONCLUSION
We report here, the first known case of PTU-induced cyanopsia.

Downloads

Download data is not yet available.

Author Biographies

Noor Hafis Md Tob

Malacca Hospital, Malaysia

Chin Voon Tong

Malacca Hospital, Malaysia

Joel Xiang Loong Lee

Malacca Hospital, Malaysia

Siow Ping Lee

Malacca Hospital, Malaysia

Melissa Vergis

Malacca Hospital, Malaysia

References

*

Downloads

Published

2023-07-06

How to Cite

Tob, N. H. M., Tong, C. V., Lee, J. X. L., Lee, S. P., & Vergis, M. (2023). SEEING BLUES ALL AROUND: A CASE OF PROPYLTHIOURACIL-INDUCED CYANOPSIA. Journal of the ASEAN Federation of Endocrine Societies, 38(S2), 58. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/3927

Most read articles by the same author(s)

<< < 1 2 3 > >>